Alzheimer's Research Takes a New Turn

Title: Alzheimer's Research Takes a New TurnCategory: Health NewsCreated: 8/13/2013 5:36:00 PMLast Editorial Review: 8/14/2013 12:00:00 AM
Source: MedicineNet Alzheimer - Category: Geriatrics Source Type: news

Related Links:

Authors: Tolar M, Abushakra S, Sabbagh M Abstract Development of disease-modifying treatments for Alzheimer's disease (AD) has been challenging, with no drugs approved to date. The failures of several amyloid-targeted programs have led many to dismiss the amyloid beta (Aβ) hypothesis of AD. An antiamyloid antibody aducanumab recently showed modest but significant efficacy in a phase 3 trial, providing important validation of amyloid as a therapeutic target. However, the inconsistent results observed with aducanumab may be explained by the limited brain penetration and lack of selectivity for the soluble A&beta...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
Authors: Nikolac Perkovic M, Pivac N Abstract Alzheimer's disease is a complex and heterogeneous, severe neurodegenerative disorder and the predominant form of dementia, characterized by cognitive disturbances, behavioral and psychotic symptoms, progressive cognitive decline, disorientation, behavioral changes, and death. Genetic background of Alzheimer's disease differs between early-onset familial Alzheimer's disease, other cases of early-onset Alzheimer's disease, and late-onset Alzheimer's disease. Rare cases of early-onset familial Alzheimer's diseases are caused by high-penetrant mutations in genes coding for...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Epileptic activity without visible convulsions is common in Alzheimer's disease (AD) and may contribute adversely to the disease progress and symptoms. Transgenic mice with amyloid plaque pathology also display epileptic seizures, but those are too infrequent to assess the effect of anti-epileptic treatments. Besides spontaneous seizures, these mice also display frequent epileptic spiking in epidural EEG recordings, and these have provided a means to test potential drug treatment to AD-related epilepsy. However, the origin of EEG spikes in transgenic AD model mice has remained elusive, which makes it difficult to relate el...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Roche is testing its "brain shuttle" in humans, with the Swiss drugmaker hoping to rejuvenate the theory that removing amyloid plaques from the brains of patients with Alzheimer's disease will prove effective despite repeated failures.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Researchers at Lawrence Berkeley National Laboratory have developed synthetic peptide-coated magnetic beads that can be used to detect the presence of misfolded proteins in blood samples. Misfolded proteins are a factor in a number of diseases, inclu...
Source: Medgadget - Category: Medical Devices Authors: Tags: Diagnostics Nanomedicine Neurology Public Health Source Type: blogs
(Technical University of Denmark) Scientists prove that ergothioneine, an important compound that may be used to delay the onset of diseases such as Alzheimer's and dementia, can be produced in baker's yeast.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
(University of Minnesota) Research update from the University of Minnesota Center for Drug Design on an early detection device for Alzheimer's disease.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
(RAND Corporation) Much work has been done to try to find a treatment that can delay or prevent the onset of Alzheimer's disease, but less attention has been paid to whether health systems could move a breakthrough into rapid clinical use. A new study finds that while Australia is better prepared than many other countries for such a development, there are steps policymakers may consider to better prepare the nation's health system.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
In 1990, Dr. Jack Kevorkian was just beginning his work in the death with dignity movement. Janet Adkins, who made a choice to die after being diagnosed with early Alzheimer’s disease, was his first assisted suicide patient. This week, Susan Clevenger publishes Dying to Die – The Janet Adkins Story. (Amazon) Clevenger interviewed and recorded stories from Janet’s family and closest friends, transcribed TV videos and read countless magazine and news stories. Her source material included Janet’s personal journals and letters from family and friends that the family had saved over the years.
Source: blog.bioethics.net - Category: Medical Ethics Authors: Tags: Health Care syndicated Source Type: blogs
This parallel-design, double-blind randomized clinical trial assesses the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 in patients with Alzheimer disease or the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome.
Source: JAMA Neurology - Category: Neurology Source Type: research
More News: Alzheimer's | Geriatrics | Health